AR120202A1 - Sales del compuesto 4-cloro-3-(2-(2-((4-((3s,5r)-3,5-dimetilpiperazin-1-il)fenil)amino)pirimidin-5-il)etil)-5-metoxi-n-metilbenzamida y formas cristalinas de las mismas - Google Patents

Sales del compuesto 4-cloro-3-(2-(2-((4-((3s,5r)-3,5-dimetilpiperazin-1-il)fenil)amino)pirimidin-5-il)etil)-5-metoxi-n-metilbenzamida y formas cristalinas de las mismas

Info

Publication number
AR120202A1
AR120202A1 ARP200102815A ARP200102815A AR120202A1 AR 120202 A1 AR120202 A1 AR 120202A1 AR P200102815 A ARP200102815 A AR P200102815A AR P200102815 A ARP200102815 A AR P200102815A AR 120202 A1 AR120202 A1 AR 120202A1
Authority
AR
Argentina
Prior art keywords
diffraction
powder
ray
characteristic
iii
Prior art date
Application number
ARP200102815A
Other languages
English (en)
Spanish (es)
Inventor
Wenji Li
Ling Feng
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of AR120202A1 publication Critical patent/AR120202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP200102815A 2019-10-14 2020-10-13 Sales del compuesto 4-cloro-3-(2-(2-((4-((3s,5r)-3,5-dimetilpiperazin-1-il)fenil)amino)pirimidin-5-il)etil)-5-metoxi-n-metilbenzamida y formas cristalinas de las mismas AR120202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910973785 2019-10-14

Publications (1)

Publication Number Publication Date
AR120202A1 true AR120202A1 (es) 2022-02-02

Family

ID=75537486

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102815A AR120202A1 (es) 2019-10-14 2020-10-13 Sales del compuesto 4-cloro-3-(2-(2-((4-((3s,5r)-3,5-dimetilpiperazin-1-il)fenil)amino)pirimidin-5-il)etil)-5-metoxi-n-metilbenzamida y formas cristalinas de las mismas

Country Status (14)

Country Link
US (2) US12559472B2 (cg-RX-API-DMAC7.html)
EP (1) EP4045484A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022552329A (cg-RX-API-DMAC7.html)
KR (1) KR20220088712A (cg-RX-API-DMAC7.html)
CN (3) CN119751422A (cg-RX-API-DMAC7.html)
AR (1) AR120202A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020367905A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007035A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154064A1 (cg-RX-API-DMAC7.html)
IL (1) IL292206B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004274A (cg-RX-API-DMAC7.html)
TW (1) TWI895290B (cg-RX-API-DMAC7.html)
UA (1) UA129777C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021073494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4450499A4 (en) * 2021-12-13 2025-12-17 Abbisko Therapeutics Co Ltd FGFR4-inhibitoric acid salt, manufacturing process and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
US20160052926A1 (en) * 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
CN107660200B (zh) * 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN110023318A (zh) * 2016-12-01 2019-07-16 和记黄埔医药(上海)有限公司 化合物的晶型

Also Published As

Publication number Publication date
TWI895290B (zh) 2025-09-01
CN114555558B (zh) 2024-12-17
CN114555558A (zh) 2022-05-27
BR112022007035A2 (pt) 2022-06-28
EP4045484A1 (en) 2022-08-24
WO2021073494A1 (en) 2021-04-22
IL292206B2 (en) 2026-03-01
US20230121346A1 (en) 2023-04-20
CA3154064A1 (en) 2021-04-22
EP4045484A4 (en) 2023-09-06
JP2025143319A (ja) 2025-10-01
US20260138967A1 (en) 2026-05-21
IL292206B1 (en) 2025-11-01
UA129777C2 (uk) 2025-07-30
US12559472B2 (en) 2026-02-24
CN119751422A (zh) 2025-04-04
CN119462616A (zh) 2025-02-18
AU2020367905A1 (en) 2022-04-21
IL292206A (en) 2022-06-01
MX2022004274A (es) 2022-05-06
TW202128669A (zh) 2021-08-01
JP2022552329A (ja) 2022-12-15
KR20220088712A (ko) 2022-06-28

Similar Documents

Publication Publication Date Title
PE20231438A1 (es) Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
ECSP20001149A (es) Compuestos antiproliferativos y métodos para utilizarlos
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
DOP2020000250A (es) Compuestos antagonistas de la pcsk9
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
CL2020001090A1 (es) Compuesto de pirimidina como inhibidor de las janocinasas.
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EA201792116A1 (ru) Ингибитор янус-киназы
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2021002575A1 (es) Compuestos de pirrol
CY1114865T1 (el) Νεοι αναστολεις seh και η χρηση toyς
AR083020A1 (es) Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden
AR120799A1 (es) 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr